FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later

Abstract

The 2008 FDA guidance for industry on cardiovascular (CV) risk of new antidiabetic therapies arose from a history of CV safety concerns brought to a head by findings with rosiglitazone and the ACCORD trial of intensive glycaemic control. This article is protected by copyright. All rights reserved.